Immunome, Inc. (NASDAQ:IMNM) Receives Average Rating of “Moderate Buy” from Brokerages

Immunome, Inc. (NASDAQ:IMNM) has been given an average recommendation of “Moderate Buy” by the ten analysts that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $23.7778.

A number of research firms recently issued reports on IMNM. Wall Street Zen downgraded shares of Immunome from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Craig Hallum assumed coverage on shares of Immunome in a research note on Friday, September 5th. They issued a “buy” rating and a $26.00 price target for the company. Evercore ISI started coverage on shares of Immunome in a research report on Friday, August 22nd. They set an “outperform” rating and a $18.00 price objective on the stock. Guggenheim reaffirmed a “buy” rating and issued a $25.00 target price on shares of Immunome in a research report on Monday, August 25th. Finally, Stephens upped their price target on Immunome from $25.00 to $33.00 and gave the stock an “overweight” rating in a research note on Monday.

Hedge Funds Weigh In On Immunome

A number of large investors have recently modified their holdings of IMNM. Primecap Management Co. CA increased its stake in Immunome by 1,115.7% during the 1st quarter. Primecap Management Co. CA now owns 3,413,700 shares of the company’s stock valued at $22,974,000 after purchasing an additional 3,132,900 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its holdings in shares of Immunome by 37.4% during the first quarter. T. Rowe Price Investment Management Inc. now owns 7,554,594 shares of the company’s stock valued at $50,843,000 after buying an additional 2,054,640 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Immunome by 43.4% during the first quarter. Vanguard Group Inc. now owns 4,307,191 shares of the company’s stock valued at $28,987,000 after buying an additional 1,303,753 shares during the last quarter. Principal Financial Group Inc. increased its position in shares of Immunome by 222.3% during the third quarter. Principal Financial Group Inc. now owns 1,104,938 shares of the company’s stock worth $12,939,000 after acquiring an additional 762,147 shares in the last quarter. Finally, Woodline Partners LP raised its holdings in shares of Immunome by 69.0% in the 1st quarter. Woodline Partners LP now owns 1,657,729 shares of the company’s stock worth $11,157,000 after acquiring an additional 676,804 shares during the last quarter. 44.58% of the stock is currently owned by institutional investors.

Immunome Price Performance

NASDAQ IMNM opened at $17.51 on Friday. The stock has a market capitalization of $1.61 billion, a P/E ratio of -5.94 and a beta of 1.96. The business has a 50 day simple moving average of $14.22 and a 200 day simple moving average of $11.03. Immunome has a one year low of $5.15 and a one year high of $18.94.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.08). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.50%. Equities analysts expect that Immunome will post -2.21 earnings per share for the current year.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.